Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BIO lawyers up

Executive Summary

The Biotechnology Industry Organization appoints Sandra Dennis to the newly created position of Deputy General Counsel for Healthcare Regulatory Affairs. The addition of Dennis serves to "enhance BIO's advocacy for a regulatory environment that allows biotechnology industry to bring ... technologies to market," BIO President Jim Greenwood says in a Jan. 9 release. The trade association is bolstering its regulatory affairs department at a time many anticipate increased Congressional interest in the establishment of a regulatory framework for approval of generic biologics (1"The Pink Sheet" Nov. 13, 2006, p. 3). Dennis comes to BIO from Morgan, Lewis & Bockius' FDA/Healthcare Regulation practice group, where she focused on regulatory, legislative, policy and corporate issues...

You may also be interested in...

Democratic Capitol Hill Will Create Challenges For Brand Industry

The sweep of both houses of Congress in the midterm elections will allow the Democrats the opportunity to push their agenda through must-pass legislation such as the reauthorization of the Prescription Drug User Fee Act

Toward The Global Big Pharma League: Yuhan’s Ambitions After Leclaza

With Leclaza as a foothold, the next couple of years will be crucial for Yuhan’s ambition to become a top 50 global pharma firm. R&D president Yeul Hong Kim shares how he intends to shape the leading Korean company's efforts to compete with its global rivals.

Pooled Procurement Of Cancer Drugs In India: Is Pharma Game For More?

India’s National Cancer Grid pilots pooled procurement for 40 drugs including trastuzumab, imatinib, and pemetrexed, delivering median savings of over 80%. Experts discuss with Scrip the prospects of scaling the initiative and what it may mean for pharma’s margins and go-to-market strategy.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts